The Wistar Institute Cancer Center presents four Type I Shared Resources in this application: Animal Facility, Flow Cytometry, Imaging, and Protein Expression. During the past project period the Cancer Center made substantial investments in the Type I Shared Resources, utilizing over $7.2 million in capital funds and equipment grants for equipment upgrades and facility improvements. These Resources function as engines, integrated components ofthe research being conducted by Cancer Center members. The Type I Resources have demonstrated a significant impact to the scientific objectives ofthe Cancer Center, contributing to 172 of 382 (45%) of the unique cancer-related publications reported by the three scientific Programs. Following a comprehensive realignment of its Shared Resources by the appointment of dedicated leadership as described in the Cancer Center Administration section of this application, Shared Resources were grouped as Type I or Type II reflecting the intensity of collaborative input of their services. Type I Shared Resources provide critical and well-defined services that require an initial consultation followed by the delivery of time/format-defined services. Collaborative input for the type of service and data analysis is often required through consultation, yet such services generally achieve or are close in achieving full recovery of operating costs through chargebacks. Clear benchmarks and objective review criteria were introduced in order to enable timely oversight, scientific impact, quality of service, and financial strength for each Shared Resource. Regular evaluations of scientific impact for the Cancer Center (i) and sustainability of services (ii) for each resource guide the decision-making process for the Shared Resources. Overall Type I Shared Resources provide an essential cornerstone for research as their impact on discovery is inherent to the reliability, innovation, and state-of-the-art service platforms delivered.

Public Health Relevance

The deployment of state-of-the-art, technologically advanced scientific capabilities has become an indispensable requirement to conduct modern cancer research. Type I Shared Resources fulfill this need by providing well-defined, personalized service to Wistar Cancer Center investigators in support of their interprogrammatic and multidisciplinary research programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8690265
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$258,701
Indirect Cost
$116,941
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tempera, Italo; De Leo, Alessandra; Kossenkov, Andrew V et al. (2016) Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol 90:345-55
Nelson, David M; Jaber-Hijazi, Farah; Cole, John J et al. (2016) Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol 17:158
Seo, Jae Ho; Rivadeneira, Dayana B; Caino, M Cecilia et al. (2016) The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biol 14:e1002507
Haut, Larissa H; Gill, Amanda L; Kurupati, Raj K et al. (2016) A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods :
Peck, Barrie; Schug, Zachary T; Zhang, Qifeng et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab 4:6
Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72
Vazquez, Alexei; Kamphorst, Jurre J; Markert, Elke K et al. (2016) Cancer metabolism at a glance. J Cell Sci 129:3367-73
Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii et al. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol 37:208-20
Kung, Che-Pei; Murphy, Maureen E (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61-R75
Patro, Sean C; Azzoni, Livio; Joseph, Jocelin et al. (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223-31

Showing the most recent 10 out of 582 publications